$0.71
3.54% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US9290331084
Symbol
VOR
Sector
Industry

Vor Biopharma Inc Stock price

$0.71
-0.18 20.36% 1M
-1.50 67.92% 6M
-1.54 68.49% YTD
-1.39 66.24% 1Y
-14.38 95.30% 3Y
-17.29 96.06% 5Y
-17.29 96.06% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.03 3.54%
ISIN
US9290331084
Symbol
VOR
Sector
Industry

Key metrics

Market capitalization $50.27m
Enterprise Value $-1.85m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.02
P/B ratio (TTM) P/B ratio 0.51
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-124.80m
Free Cash Flow (TTM) Free Cash Flow $-104.94m
Cash position $85.94m
EPS (TTM) EPS $-1.74
P/E forward negative
Short interest 4.18%
Show more

Is Vor Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Vor Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Vor Biopharma Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Vor Biopharma Inc forecast:

Buy
100%

Financial data from Vor Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 4.82 4.82
49% 49%
-
-4.82 -4.82
49% 49%
-
- Selling and Administrative Expenses 21 21
61% 61%
-
- Research and Development Expense 95 95
19% 19%
-
-120 -120
18% 18%
-
- Depreciation and Amortization 4.82 4.82
49% 49%
-
EBIT (Operating Income) EBIT -125 -125
12% 12%
-
Net Profit -118 -118
11% 11%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vor Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vor Biopharma Inc Stock News

Neutral
GlobeNewsWire
22 days ago
CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg t...
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
about 2 months ago
CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2024, and provided a corporate update.
More Vor Biopharma Inc News

Company Profile

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Bob Ang
Employees 168
Founded 2015
Website www.vorbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today